Trends in Cases, Hospitalizations, and Mortality Related to the Omicron BA.4/BA.5 Subvariants in South Africa

被引:19
|
作者
Jassat, Waasila [1 ,2 ]
Karim, Salim S. Abdool [3 ,4 ]
Ozougwu, Lovelyn [1 ,2 ]
Welch, Richard [1 ,2 ]
Mudara, Caroline [1 ]
Masha, Maureen [1 ,2 ]
Rousseau, Petro [5 ]
Wolmarans, Milani [5 ]
Selikow, Anthony [6 ]
Govender, Nevashan [1 ]
Walaza, Sibongile [1 ,7 ]
von Gottberg, Anne [1 ,8 ]
Wolter, Nicole [1 ,8 ]
Pisa, Pedro Terrence [2 ,9 ]
Sanne, Ian [2 ,10 ]
Govender, Sharlene [2 ]
Blumberg, Lucille [1 ,2 ]
Cohen, Cheryl [1 ]
Groome, Michelle J. [1 ,8 ]
机构
[1] Natl Inst Communicable Dis, Div Natl Hlth Lab Serv, 1 Modderfontein Rd, ZA-2192 Johannesburg, South Africa
[2] Right Care, Pretoria, South Africa
[3] Ctr AIDS Programme Res South Afr, Durban, South Africa
[4] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA
[5] Natl Dept Hlth, Pretoria, South Africa
[6] CSIR, Pretoria, South Africa
[7] Univ Witwatersrand, Fac Hlth Sci, Sch Publ Hlth, Johannesburg, South Africa
[8] Univ Witwatersrand, Fac Hlth Sci, Sch Pathol, Johannesburg, South Africa
[9] Univ Pretoria, Fac Hlth Sci, Dept Human Nutr & Dietet, Pretoria, South Africa
[10] Univ Witwatersrand, Fac Hlth Sci, Dept Internal Med, Clin HIV Res Unit, Johannesburg, South Africa
关键词
COVID-19; hospital admissions; mortality; Omicron BA; 4; 5;
D O I
10.1093/cid/ciac921
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Admission incidence risk and in-hospital mortality decreased in the Omicron BA.1/BA.2 wave, reducing even further in the Omicron BA.4/BA.5 wave. Mortality risk was lower in those with natural infection and vaccination, declining further as the number of vaccine doses increased. Background In this study, we compared admission incidence risk and the risk of mortality in the Omicron BA.4/BA.5 wave to previous waves. Methods Data from South Africa's SARS-CoV-2 case linelist, national COVID-19 hospital surveillance system, and Electronic Vaccine Data System were linked and analyzed. Wave periods were defined when the country passed a weekly incidence of 30 cases/100 000 population. In-hospital case fatality ratios (CFRs) during the Delta, Omicron BA.1/BA.2, and Omicron BA.4/BA.5 waves were compared using post-imputation random effect multivariable logistic regression models. Results The CFR was 25.9% (N = 37 538 of 144 778), 10.9% (N = 6123 of 56 384), and 8.2% (N = 1212 of 14 879) in the Delta, Omicron BA.1/BA.2, and Omicron BA.4/BA.5 waves, respectively. After adjusting for age, sex, race, comorbidities, health sector, and province, compared with the Omicron BA.4/BA.5 wave, patients had higher risk of mortality in the Omicron BA.1/BA.2 wave (adjusted odds ratio [aOR], 1.3; 95% confidence interval [CI]: 1.2-1.4) and Delta wave (aOR, 3.0; 95% CI: 2.8-3.2). Being partially vaccinated (aOR, 0.9; 95% CI: .9-.9), fully vaccinated (aOR, 0.6; 95% CI: .6-.7), and boosted (aOR, 0.4; 95% CI: .4-.5) and having prior laboratory-confirmed infection (aOR, 0.4; 95% CI: .3-.4) were associated with reduced risks of mortality. Conclusions Overall, admission incidence risk and in-hospital mortality, which had increased progressively in South Africa's first 3 waves, decreased in the fourth Omicron BA.1/BA.2 wave and declined even further in the fifth Omicron BA.4/BA.5 wave. Mortality risk was lower in those with natural infection and vaccination, declining further as the number of vaccine doses increased.
引用
收藏
页码:1468 / 1475
页数:8
相关论文
共 50 条
  • [21] Results of contact tracing for SARS-CoV-2 Omicron sub-lineages (BA.4, BA.5, BA.2.75) and the household secondary attack risk
    Yu, Mi
    Lee, Sang-Eun
    Lee, Hye Young
    Kim, Hye-Jin
    Song, Yeong-Jun
    Jeong, Jian
    Park, Ae Kyung
    Kim, Il-Hwan
    Kim, Eun-Jin
    Park, Young-Joon
    OSONG PUBLIC HEALTH AND RESEARCH PERSPECTIVES, 2023, 14 (03) : 173 - 179
  • [22] Clinical severity of Omicron subvariants BA.1, BA.2, and BA.5 in a population-based cohort study in British Columbia, Canada
    Russell, Shannon L.
    Klaver, Braeden R. A.
    Harrigan, Sean P.
    Kamelian, Kimia
    Tyson, John
    Hoang, Linda
    Taylor, Marsha
    Sander, Beate
    Mishra, Sharmistha
    Prystajecky, Natalie
    Janjua, Naveed Z.
    Zlosnik, James E. A.
    Sbihi, Hind
    JOURNAL OF MEDICAL VIROLOGY, 2023, 95 (01)
  • [23] Bivalent Omicron BA.4/BA.5 BNT162b2 Vaccine in 6-Month- to <12-Year-Olds
    Sher, Lawrence D.
    Boakye-Appiah, Justice K.
    Hill, Sungeen
    Wasserman, Emily
    Xu, Xia
    Maldonado, Yvonne
    Walter, Emmanuel B.
    Munoz, Flor M.
    Paulsen, Grant C.
    Englund, Janet A.
    Talaat, Kawsar R.
    Barnett, Elizabeth D.
    Kamidani, Satoshi
    Senders, Shelly
    Simoes, Eric A. F.
    Belanger, Kelly
    Parikh, Vrunda
    Ma, Hua
    Wang, Xingbin
    Lu, Claire
    Cooper, David
    Koury, Kenneth
    Anderson, Annaliesa S.
    Tuereci, Oezlem
    Sahin, Ugur
    Swanson, Kena A.
    Gruber, William C.
    Gurtman, Alejandra
    Kitchin, Nicholas
    Sabharwal, Charu
    JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY, 2024, 13 (08) : 421 - 429
  • [24] SARS-CoV-2 Omicron (BA.4, BA.5) variant: Lessons learned from a new variant during the COVID-19 pandemic
    Erabi, Gisou
    Faridzadeh, Arezoo
    Parvin, Ali
    Deravi, Niloofar
    Rahmanian, Mohammad
    Fathi, Mobina
    Aleebrahim-Dehkordi, Elahe
    Rezaei, Nima
    HEALTH SCIENCE REPORTS, 2024, 7 (02)
  • [25] Evolution of SARS-CoV-2: BA.4/BA.5 Variants Continues to Pose New Challenges
    Quadir, Neha
    Singh, Jasdeep
    Alam, Anwar
    Malik, Asrar Ahmad
    Rahman, Syed Asad
    Hira, Subhash
    Ehtesham, Nasreen Zafar
    Sundar, Durai
    Hasnain, Seyed Ehtesham
    VIRUSES-BASEL, 2022, 14 (12):
  • [26] Neutralization of Omicron subvariants BA.1 and BA.5 by a booster dose of COVID-19 mRNA vaccine in a Japanese nursing home cohort
    Itamochi, Masae
    Yazawa, Shunsuke
    Inasaki, Noriko
    Saga, Yumiko
    Yamazaki, Emiko
    Shimada, Takahisa
    Tamura, Kosuke
    Maenishi, Emi
    Isobe, Junko
    Nakamura, Masahiko
    Takaoka, Misuzu
    Sasajima, Hitoshi
    Kawashiri, Chikako
    Tani, Hideki
    Oishi, Kazunori
    VACCINE, 2023, 41 (13) : 2234 - 2242
  • [27] Protection Conferred by Delta and BA.1/BA.2 Infection Against BA.4/BA.5 Infection and Hospitalization: A Retrospective Cohort Study
    Winchester, Nicole E.
    Shrestha, Nabin K.
    Kim, Priscilla
    Tereshchenko, Larisa G.
    Rothberg, Michael B.
    JOURNAL OF INFECTIOUS DISEASES, 2023, 227 (06) : 800 - 805
  • [28] Vaccination and Omicron BA.1/BA.2 Convalescence Enhance Systemic but Not Mucosal Immunity against BA.4/5
    Diem, Gabriel
    Jaeger, Michael
    Dichtl, Stefanie
    Bauer, Angelika
    Lass-Floerl, Cornelia
    Reindl, Markus
    Wilflingseder, Doris
    Posch, Wilfried
    MICROBIOLOGY SPECTRUM, 2023, 11 (03):
  • [29] Real-world nirmatrelvir-ritonavir outpatient treatment in reducing hospitalization for high-risk patients with COVID-19 during Omicron BA.4, BA.5 and XBB subvariants dominance in Malaysia: A retrospective cohort study
    Low, Ee Vien
    Pathmanathan, Mohan Dass
    Chidambaram, Suresh Kumar
    Kim, Wee Ric
    Lee, Wei Jia
    Teh, Zhi Wei
    Appannan, Maheshwara Rao
    Zin, Shahanizan Mohd
    Zin, Faizah Muhamad
    Amin, Samha Bashirah Mohamed
    Ismail, Mastura
    Samad, Azah Abdul
    Peariasamy, Kalaiarasu M.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2023, 135 : 77 - 83
  • [30] Immunity of Heterologously and Homologously Boosted or Convalescent Individuals Against Omicron BA.1, BA.2, and BA.4/5 Variants
    Jaeger, Michael
    Diem, Gabriel
    Sahanic, Sabina
    Fux, Vilmos
    Griesmacher, Andrea
    Lass-Floerl, Cornelia
    Wilflingseder, Doris
    Tancevski, Ivan
    Posch, Wilfried
    JOURNAL OF INFECTIOUS DISEASES, 2023, 228 (02) : 160 - 168